Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyCholestyramine
Identification
- Name
- Cholestyramine
- Accession Number
- DB01432
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
- Synonyms
- Cholestyramine resin
- Colestyramine
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Cholestyramine Powder, for suspension 4 g Oral Sorres Pharma Inc 1998-02-17 2010-10-06 Canada 
Cholestyramine Powder, for suspension 4 g Oral Sorres Pharma Inc 1998-02-17 2010-10-19 Canada Cholestyramine-odan Powder, for suspension 4 g Oral Odan Laboratories Ltd 2016-12-23 Not applicable Canada Olestyr Powder, for suspension 4 g Oral Pharmascience Inc 1996-03-15 Not applicable Canada Olestyr Powder, for suspension 4 g Oral Pharmascience Inc 1993-12-31 Not applicable Canada Questran Light Pws 4gm/pck Powder, for solution 4 g Oral Bristol Labs Division Of Bristol Myers Squibb 1991-12-31 2005-08-01 Canada Questran Pwr 378gm/can Powder, for solution 4 g Oral Bristol Labs Division Of Bristol Myers Squibb 1985-12-31 2005-08-01 Canada Questran Pwr 4gm/9gm Powder, for solution 4 g Oral Bristol Labs Division Of Bristol Myers Squibb 1979-12-31 2005-08-01 Canada Questran Tab 1gm Tablet 1 g Oral Bristol Myers Squibb 1993-12-31 1999-08-09 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Alti-cholestyramine Light Kit; Powder 4 g Oral Altimed Pharma Inc. 1994-12-31 1999-09-17 Canada Cholestyramine Powder, for suspension 4 g/9g Oral Physicians Total Care, Inc. 2010-03-22 Not applicable US 
Cholestyramine Powder, for suspension 4 g/9g Oral Eon Labs, Inc. 1996-08-15 Not applicable US Cholestyramine Powder, for suspension 4 g/9g Oral Par Pharmaceutical 2005-09-15 Not applicable US Cholestyramine Powder, for suspension 4 g/9g Oral Golden State Medical Supply 2005-09-15 2017-10-26 US Cholestyramine Powder, for suspension 4 g/9g Oral Upsher Smith Laboratories 2012-01-05 Not applicable US Cholestyramine Powder, for suspension 4 g/5.5g Oral Cadila Pharnmaceuticals 2017-06-08 Not applicable US Cholestyramine Powder, for suspension 4 g/5g Oral Physicians Total Care, Inc. 2006-02-08 Not applicable US Cholestyramine Powder, for suspension 4 g/5g Oral Par Pharmaceutical 2005-09-15 Not applicable US Cholestyramine Powder, for suspension 4 g/5.5g Oral Zydus Pharmaceuticals Usa, Inc. 2017-06-08 Not applicable US - International/Other Brands
- Cholybar / Locholest / Locholest light / Questran Light
- Categories
- Anion Exchange Resins
- Anticholesteremic Agents
- Benzene Derivatives
- Benzylidene Compounds
- Bile Acid Sequestrants
- Biomedical and Dental Materials
- Cardiovascular System
- Hypolipidemic Agents
- Ion Exchange Resins
- Laboratory Chemicals
- Lipid Modifying Agents
- Lipid Modifying Agents, Plain
- Lipid Regulating Agents
- Macromolecular Substances
- Noxae
- Plastics
- Polymers
- Polystyrenes
- Styrene
- Styrenes
- Toxic Actions
- UNII
- 4B33BGI082
- CAS number
- 11041-12-6
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.
- Associated Conditions
- Pharmacodynamics
Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum. Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.
- Mechanism of action
Cholestyramine binds bile in the gastrointestinal tract to prevent its reabsorption. The resin is a strong anion exchange resin, which means that it can exchange its chloride anions with anionic bile acids in the gastrointestinal tract and bind them strongly in the resin matrix. The functional group of the anion exchange resin is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer.
Target Actions Organism ABile acids binderHuman - Absorption
Not absorbed from the gastrointestinal tract following oral administration.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Bile acids
- Route of elimination
Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces.
- Half life
6 minutes
- Clearance
- Not Available
- Toxicity
Overdose may result in blockage of intestine or stomach.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene Cholestyramine can cause a decrease in the absorption of (4R)-limonene resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational 16-Bromoepiandrosterone Cholestyramine can cause a decrease in the absorption of 16-Bromoepiandrosterone resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational 19-norandrostenedione Cholestyramine can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Illicit 5-androstenedione Cholestyramine can cause a decrease in the absorption of 5-androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Illicit Aceclofenac Cholestyramine can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Acemetacin Cholestyramine can cause a decrease in the absorption of Acemetacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Acenocoumarol Cholestyramine can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Acetaminophen Cholestyramine can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Acetyldigitoxin Cholestyramine can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Acetyldigoxin Cholestyramine can cause a decrease in the absorption of Acetyldigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Acetylsalicylic acid Cholestyramine can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Adapalene Cholestyramine can cause a decrease in the absorption of Adapalene resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Alclofenac Cholestyramine can cause a decrease in the absorption of Alclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Alclometasone Cholestyramine can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Aldosterone Cholestyramine can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Investigational Alfacalcidol The serum concentration of Alfacalcidol can be decreased when it is combined with Cholestyramine. Approved, Nutraceutical Alminoprofen Cholestyramine can cause a decrease in the absorption of Alminoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium clofibrate Cholestyramine can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Amcinonide Cholestyramine can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Amiodarone The serum concentration of Amiodarone can be decreased when it is combined with Cholestyramine. Approved, Investigational Andrographolide Cholestyramine can cause a decrease in the absorption of Andrographolide resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Androstenedione Cholestyramine can cause a decrease in the absorption of Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Illicit Anecortave Cholestyramine can cause a decrease in the absorption of Anecortave resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational anecortave acetate Cholestyramine can cause a decrease in the absorption of anecortave acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Anisodamine Cholestyramine can cause a decrease in the absorption of Anisodamine resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Antipyrine Cholestyramine can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Apocynin Cholestyramine can cause a decrease in the absorption of Apocynin resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Apremilast Cholestyramine can cause a decrease in the absorption of Apremilast resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Atamestane Cholestyramine can cause a decrease in the absorption of Atamestane resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Atorvastatin Cholestyramine can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Azapropazone Cholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Withdrawn Azelastine Cholestyramine can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Azosemide Cholestyramine can cause a decrease in the absorption of Azosemide resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Balsalazide Cholestyramine can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Beclomethasone dipropionate Cholestyramine can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Bendazac Cholestyramine can cause a decrease in the absorption of Bendazac resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Bendroflumethiazide Cholestyramine can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Benorilate Cholestyramine can cause a decrease in the absorption of Benorilate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Benoxaprofen Cholestyramine can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Withdrawn Benzthiazide Cholestyramine can cause a decrease in the absorption of Benzthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Benzydamine Cholestyramine can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Betamethasone Cholestyramine can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Bevonium Cholestyramine can cause a decrease in the absorption of Bevonium resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Bezafibrate Cholestyramine can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Bromfenac Cholestyramine can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Bucillamine Cholestyramine can cause a decrease in the absorption of Bucillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Budesonide Cholestyramine can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Bufexamac Cholestyramine can cause a decrease in the absorption of Bufexamac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Bumadizone Cholestyramine can cause a decrease in the absorption of Bumadizone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Bumetanide Cholestyramine can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcidiol The serum concentration of Calcidiol can be decreased when it is combined with Cholestyramine. Approved, Nutraceutical Calcipotriol The serum concentration of Calcipotriol can be decreased when it is combined with Cholestyramine. Approved Calcitriol The serum concentration of Calcitriol can be decreased when it is combined with Cholestyramine. Approved, Nutraceutical Carbaspirin calcium Cholestyramine can cause a decrease in the absorption of Carbaspirin calcium resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Investigational Carprofen Cholestyramine can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved, Withdrawn Castanospermine Cholestyramine can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Celecoxib Cholestyramine can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Cerivastatin Cholestyramine can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Chenodeoxycholic acid The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Cholestyramine. Approved Chlormadinone The serum concentration of Chlormadinone can be decreased when it is combined with Cholestyramine. Experimental Chloroquine Cholestyramine can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Chlorothiazide Cholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Chlortetracycline Cholestyramine can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Chlorthalidone Cholestyramine can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cholecalciferol The serum concentration of Cholecalciferol can be decreased when it is combined with Cholestyramine. Approved, Nutraceutical Cholic Acid Cholestyramine can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Choline magnesium trisalicylate Cholestyramine can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ciclesonide Cholestyramine can cause a decrease in the absorption of Ciclesonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Ciprofibrate Cholestyramine can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Clobetasol Cholestyramine can cause a decrease in the absorption of Clobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Clobetasol propionate Cholestyramine can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Clobetasone Cholestyramine can cause a decrease in the absorption of Clobetasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Clocortolone Cholestyramine can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Clofibrate Cholestyramine can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Clofibride Cholestyramine can cause a decrease in the absorption of Clofibride resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Clonixin Cholestyramine can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Clorindione Cholestyramine can cause a decrease in the absorption of Clorindione resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Cortexolone 17α-propionate Cholestyramine can cause a decrease in the absorption of Cortexolone 17α-propionate resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Corticosterone Cholestyramine can cause a decrease in the absorption of Corticosterone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Cortisone acetate Cholestyramine can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Curcumin Cholestyramine can cause a decrease in the absorption of Curcumin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Cyclopenthiazide Cholestyramine can cause a decrease in the absorption of Cyclopenthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Cymarin Cholestyramine can cause a decrease in the absorption of Cymarin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Cyproterone acetate The serum concentration of Cyproterone acetate can be decreased when it is combined with Cholestyramine. Approved, Investigational Deferasirox The serum concentration of Deferasirox can be decreased when it is combined with Cholestyramine. Approved, Investigational Deflazacort Cholestyramine can cause a decrease in the absorption of Deflazacort resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Demeclocycline Cholestyramine can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Deslanoside Cholestyramine can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Desogestrel The serum concentration of Desogestrel can be decreased when it is combined with Cholestyramine. Approved Desonide Cholestyramine can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Desoximetasone Cholestyramine can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Desoxycorticosterone acetate Cholestyramine can cause a decrease in the absorption of Desoxycorticosterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Desoxycorticosterone Pivalate Cholestyramine can cause a decrease in the absorption of Desoxycorticosterone Pivalate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Vet Approved Dexamethasone Cholestyramine can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Cholestyramine can cause a decrease in the absorption of Dexamethasone isonicotinate resulting in a reduced serum concentration and potentially a decrease in efficacy. Vet Approved Diclofenac Cholestyramine can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Dicoumarol Cholestyramine can cause a decrease in the absorption of Dicoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Dienogest The serum concentration of Dienogest can be decreased when it is combined with Cholestyramine. Approved Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Cholestyramine. Approved, Investigational Difenpiramide Cholestyramine can cause a decrease in the absorption of Difenpiramide resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Diflorasone Cholestyramine can cause a decrease in the absorption of Diflorasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Diflunisal Cholestyramine can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Difluocortolone Cholestyramine can cause a decrease in the absorption of Difluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Withdrawn Difluprednate Cholestyramine can cause a decrease in the absorption of Difluprednate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Digitoxin Cholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Digoxin Cholestyramine can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Digoxin Immune Fab (Ovine) Cholestyramine can cause a decrease in the absorption of Digoxin Immune Fab (Ovine) resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Dihydrotachysterol The serum concentration of Dihydrotachysterol can be decreased when it is combined with Cholestyramine. Approved Diphenadione Cholestyramine can cause a decrease in the absorption of Diphenadione resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Doxercalciferol The serum concentration of Doxercalciferol can be decreased when it is combined with Cholestyramine. Approved Doxycycline Cholestyramine can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Drospirenone The serum concentration of Drospirenone can be decreased when it is combined with Cholestyramine. Approved Droxicam Cholestyramine can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. Withdrawn Duvelisib Cholestyramine can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational E-6201 Cholestyramine can cause a decrease in the absorption of E-6201 resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Epirizole Cholestyramine can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Epitizide Cholestyramine can cause a decrease in the absorption of Epitizide resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Equilenin Cholestyramine can cause a decrease in the absorption of Equilenin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Equilin Cholestyramine can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ergocalciferol The serum concentration of Ergocalciferol can be decreased when it is combined with Cholestyramine. Approved, Nutraceutical Estradiol The serum concentration of Estradiol can be decreased when it is combined with Cholestyramine. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Estradiol cypionate can be decreased when it is combined with Cholestyramine. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Estradiol valerate can be decreased when it is combined with Cholestyramine. Approved, Investigational, Vet Approved Estrone Cholestyramine can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Estrone sulfate Cholestyramine can cause a decrease in the absorption of Estrone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Etacrynic acid Cholestyramine can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Etanercept Cholestyramine can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Ethenzamide Cholestyramine can cause a decrease in the absorption of Ethenzamide resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cholestyramine. Approved Ethyl biscoumacetate Cholestyramine can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Withdrawn Ethynodiol diacetate The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Cholestyramine. Approved Etodolac Cholestyramine can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Etofenamate Cholestyramine can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Etofibrate Cholestyramine can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Etonogestrel The serum concentration of Etonogestrel can be decreased when it is combined with Cholestyramine. Approved, Investigational Etoricoxib Cholestyramine can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Evening primrose oil Cholestyramine can cause a decrease in the absorption of Evening primrose oil resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational, Nutraceutical Exisulind Cholestyramine can cause a decrease in the absorption of Exisulind resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Ezetimibe Cholestyramine can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Felbinac Cholestyramine can cause a decrease in the absorption of Felbinac resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Fenbufen Cholestyramine can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Fenofibrate Cholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Fenofibric acid Cholestyramine can cause a decrease in the absorption of Fenofibric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Fenoprofen Cholestyramine can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Fentiazac Cholestyramine can cause a decrease in the absorption of Fentiazac resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Feprazone Cholestyramine can cause a decrease in the absorption of Feprazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Ferulic acid Cholestyramine can cause a decrease in the absorption of Ferulic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Floctafenine Cholestyramine can cause a decrease in the absorption of Floctafenine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Fluasterone Cholestyramine can cause a decrease in the absorption of Fluasterone resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Fludrocortisone Cholestyramine can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Fluindione Cholestyramine can cause a decrease in the absorption of Fluindione resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Flumethasone Cholestyramine can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Flunisolide Cholestyramine can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Flunixin Cholestyramine can cause a decrease in the absorption of Flunixin resulting in a reduced serum concentration and potentially a decrease in efficacy. Vet Approved Flunoxaprofen Cholestyramine can cause a decrease in the absorption of Flunoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Fluocinolone Acetonide Cholestyramine can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Fluocinonide Cholestyramine can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Fluocortolone Cholestyramine can cause a decrease in the absorption of Fluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Fluorometholone Cholestyramine can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Fluprednidene Cholestyramine can cause a decrease in the absorption of Fluprednidene resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Fluprednisolone Cholestyramine can cause a decrease in the absorption of Fluprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Flurandrenolide Cholestyramine can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Flurbiprofen Cholestyramine can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Fluticasone Cholestyramine can cause a decrease in the absorption of Fluticasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Fluticasone furoate Cholestyramine can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Fluticasone propionate Cholestyramine can cause a decrease in the absorption of Fluticasone propionate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Fluvastatin The serum concentration of Fluvastatin can be decreased when it is combined with Cholestyramine. Approved Formestane Cholestyramine can cause a decrease in the absorption of Formestane resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Withdrawn Furosemide Cholestyramine can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Gemfibrozil Cholestyramine can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Gestodene The serum concentration of Gestodene can be decreased when it is combined with Cholestyramine. Approved, Investigational Gestrinone The serum concentration of Gestrinone can be decreased when it is combined with Cholestyramine. Approved Gitoformate Cholestyramine can cause a decrease in the absorption of Gitoformate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Guacetisal Cholestyramine can cause a decrease in the absorption of Guacetisal resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Halcinonide Cholestyramine can cause a decrease in the absorption of Halcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Withdrawn HE3286 Cholestyramine can cause a decrease in the absorption of HE3286 resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Higenamine Cholestyramine can cause a decrease in the absorption of Higenamine resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Hydrochlorothiazide Cholestyramine can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Hydrocortisone Cholestyramine can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Hydroflumethiazide Cholestyramine can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Hydroxyprogesterone caproate The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Cholestyramine. Approved, Investigational Ibuprofen Cholestyramine can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ibuproxam Cholestyramine can cause a decrease in the absorption of Ibuproxam resulting in a reduced serum concentration and potentially a decrease in efficacy. Withdrawn Icatibant Cholestyramine can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Imidazole salicylate Cholestyramine can cause a decrease in the absorption of Imidazole salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Indapamide Cholestyramine can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Indobufen Cholestyramine can cause a decrease in the absorption of Indobufen resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Indomethacin Cholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Indoprofen Cholestyramine can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Withdrawn Isoxicam Cholestyramine can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. Withdrawn Istaroxime Cholestyramine can cause a decrease in the absorption of Istaroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Kebuzone Cholestyramine can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Ketoprofen Cholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Ketorolac Cholestyramine can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Lanatoside C Cholestyramine can cause a decrease in the absorption of Lanatoside C resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Leflunomide The serum concentration of the active metabolites of Leflunomide can be reduced when Leflunomide is used in combination with Cholestyramine resulting in a loss in efficacy. Approved, Investigational Levomefolic acid The serum concentration of Levomefolic acid can be decreased when it is combined with Cholestyramine. Approved, Investigational Levonorgestrel The serum concentration of Levonorgestrel can be decreased when it is combined with Cholestyramine. Approved, Investigational Levothyroxine The serum concentration of Levothyroxine can be decreased when it is combined with Cholestyramine. Approved Liothyronine The serum concentration of Liothyronine can be decreased when it is combined with Cholestyramine. Approved, Vet Approved Liotrix The serum concentration of Liotrix can be decreased when it is combined with Cholestyramine. Approved Lipegfilgrastim Cholestyramine may increase the myelosuppressive activities of Lipegfilgrastim. Approved, Investigational Lisofylline Cholestyramine can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Lomitapide Cholestyramine can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Lonazolac Cholestyramine can cause a decrease in the absorption of Lonazolac resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Lornoxicam Cholestyramine can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Loteprednol Cholestyramine can cause a decrease in the absorption of Loteprednol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Lovastatin Cholestyramine can cause a decrease in the absorption of Lovastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Loxoprofen Cholestyramine can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Lumiracoxib Cholestyramine can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Lynestrenol The serum concentration of Lynestrenol can be decreased when it is combined with Cholestyramine. Approved, Investigational Magnesium salicylate Cholestyramine can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Masoprocol Cholestyramine can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational ME-609 Cholestyramine can cause a decrease in the absorption of ME-609 resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Meclofenamic acid Cholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Medroxyprogesterone acetate The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Cholestyramine. Approved, Investigational Medrysone Cholestyramine can cause a decrease in the absorption of Medrysone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Mefenamic acid Cholestyramine can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Megestrol acetate The serum concentration of Megestrol acetate can be decreased when it is combined with Cholestyramine. Approved, Investigational, Vet Approved Melengestrol Cholestyramine can cause a decrease in the absorption of Melengestrol resulting in a reduced serum concentration and potentially a decrease in efficacy. Vet Approved Meloxicam Cholestyramine can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Mesalazine Cholestyramine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Mestranol The serum concentration of Mestranol can be decreased when it is combined with Cholestyramine. Approved Metamizole Cholestyramine can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Withdrawn Methotrexate Cholestyramine can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Methyclothiazide Cholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Methylprednisolone Cholestyramine can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Metildigoxin Cholestyramine can cause a decrease in the absorption of Metildigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Metolazone Cholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Mevastatin Cholestyramine can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Minocycline Cholestyramine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Mizoribine Cholestyramine can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Mofebutazone Cholestyramine can cause a decrease in the absorption of Mofebutazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Mometasone Cholestyramine can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Mycophenolate mofetil Cholestyramine can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Cholestyramine. Approved Nabumetone Cholestyramine can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Nafamostat Cholestyramine can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Naftifine Cholestyramine can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Naproxen Cholestyramine can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved NCX 1022 Cholestyramine can cause a decrease in the absorption of NCX 1022 resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Nepafenac Cholestyramine can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Niacin Cholestyramine can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Nutraceutical Nifenazone Cholestyramine can cause a decrease in the absorption of Nifenazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Niflumic Acid Cholestyramine can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Nimesulide Cholestyramine can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Withdrawn Nitroaspirin Cholestyramine can cause a decrease in the absorption of Nitroaspirin resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Nomegestrol acetate The serum concentration of Nomegestrol acetate can be decreased when it is combined with Cholestyramine. Approved, Investigational Norelgestromin The serum concentration of Norelgestromin can be decreased when it is combined with Cholestyramine. Approved, Investigational Norethisterone The serum concentration of Norethisterone can be decreased when it is combined with Cholestyramine. Approved Norethynodrel The serum concentration of Norethynodrel can be decreased when it is combined with Cholestyramine. Approved Norgestimate The serum concentration of Norgestimate can be decreased when it is combined with Cholestyramine. Approved, Investigational Norgestrel The serum concentration of Norgestrel can be decreased when it is combined with Cholestyramine. Approved Norgestrienone The serum concentration of Norgestrienone can be decreased when it is combined with Cholestyramine. Experimental Oleandrin Cholestyramine can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Investigational Oleoyl-estrone Cholestyramine can cause a decrease in the absorption of Oleoyl-estrone resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Olopatadine Cholestyramine can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Olsalazine Cholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Orgotein Cholestyramine can cause a decrease in the absorption of Orgotein resulting in a reduced serum concentration and potentially a decrease in efficacy. Vet Approved Ouabain Cholestyramine can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Oxaprozin Cholestyramine can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Oxyphenbutazone Cholestyramine can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Oxytetracycline Cholestyramine can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Palmidrol Cholestyramine can cause a decrease in the absorption of Palmidrol resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Nutraceutical Paramethasone Cholestyramine can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Parecoxib Cholestyramine can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Paricalcitol The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. Approved, Investigational Parthenolide Cholestyramine can cause a decrease in the absorption of Parthenolide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Peruvoside Cholestyramine can cause a decrease in the absorption of Peruvoside resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Phenindione Cholestyramine can cause a decrease in the absorption of Phenindione resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Phenobarbital The serum concentration of Phenobarbital can be decreased when it is combined with Cholestyramine. Approved, Investigational Phenprocoumon Cholestyramine can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Phenylbutazone Cholestyramine can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Pimecrolimus Cholestyramine can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Piretanide Cholestyramine can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Pirfenidone Cholestyramine can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Piroxicam Cholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Pirprofen Cholestyramine can cause a decrease in the absorption of Pirprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Pitavastatin Cholestyramine can cause a decrease in the absorption of Pitavastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Polythiazide Cholestyramine can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Pranoprofen Cholestyramine can cause a decrease in the absorption of Pranoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental, Investigational Prasterone Cholestyramine can cause a decrease in the absorption of Prasterone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Nutraceutical Prasterone sulfate Cholestyramine can cause a decrease in the absorption of Prasterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Pravastatin Cholestyramine can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Prednicarbate Cholestyramine can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Prednisolone Cholestyramine can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Prednisone Cholestyramine can cause a decrease in the absorption of Prednisone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Pregnenolone Cholestyramine can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Proglumetacin Cholestyramine can cause a decrease in the absorption of Proglumetacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Propacetamol Cholestyramine can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Propranolol The serum concentration of Propranolol can be decreased when it is combined with Cholestyramine. Approved, Investigational Propyphenazone Cholestyramine can cause a decrease in the absorption of Propyphenazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Proquazone Cholestyramine can cause a decrease in the absorption of Proquazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Proscillaridin Cholestyramine can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental PTC299 Cholestyramine can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Quinethazone Cholestyramine can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Quingestanol The serum concentration of Quingestanol can be decreased when it is combined with Cholestyramine. Experimental Raloxifene Cholestyramine can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Resveratrol Cholestyramine can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Rimexolone Cholestyramine can cause a decrease in the absorption of Rimexolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Rofecoxib Cholestyramine can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Withdrawn Ronifibrate Cholestyramine can cause a decrease in the absorption of Ronifibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Rosiglitazone The serum concentration of Rosiglitazone can be decreased when it is combined with Cholestyramine. Approved, Investigational Rosuvastatin Cholestyramine can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Salicylamide Cholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Salicylic acid Cholestyramine can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Salsalate Cholestyramine can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Semapimod Cholestyramine can cause a decrease in the absorption of Semapimod resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Seratrodast Cholestyramine can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Serrapeptase Cholestyramine can cause a decrease in the absorption of Serrapeptase resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Simfibrate Cholestyramine can cause a decrease in the absorption of Simfibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Simvastatin Cholestyramine can cause a decrease in the absorption of Simvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Spironolactone The risk or severity of adverse effects can be increased when Cholestyramine is combined with Spironolactone. Approved SRT501 Cholestyramine can cause a decrease in the absorption of SRT501 resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Sulfasalazine Cholestyramine can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sulindac Cholestyramine can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Suprofen Cholestyramine can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Suxibuzone Cholestyramine can cause a decrease in the absorption of Suxibuzone resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Tarenflurbil Cholestyramine can cause a decrease in the absorption of Tarenflurbil resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Tenidap Cholestyramine can cause a decrease in the absorption of Tenidap resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Tenoxicam Cholestyramine can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Tepoxalin Cholestyramine can cause a decrease in the absorption of Tepoxalin resulting in a reduced serum concentration and potentially a decrease in efficacy. Vet Approved Teriflunomide The serum concentration of Teriflunomide can be decreased when it is combined with Cholestyramine. Approved Tetracycline Cholestyramine can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Thyroid, porcine The serum concentration of Thyroid, porcine can be decreased when it is combined with Cholestyramine. Approved Tiaprofenic acid Cholestyramine can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Tinoridine Cholestyramine can cause a decrease in the absorption of Tinoridine resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Tioclomarol Cholestyramine can cause a decrease in the absorption of Tioclomarol resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Tixocortol Cholestyramine can cause a decrease in the absorption of Tixocortol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Tolfenamic Acid Cholestyramine can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Tolmetin Cholestyramine can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Torasemide Cholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Tranilast Cholestyramine can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Triamcinolone Cholestyramine can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Tribenoside Cholestyramine can cause a decrease in the absorption of Tribenoside resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Trichlormethiazide Cholestyramine can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Triptolide Cholestyramine can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy. Investigational Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Cholestyramine. Approved Ulobetasol Cholestyramine can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ursodeoxycholic acid The serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Cholestyramine. Approved, Investigational Valdecoxib Cholestyramine can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Withdrawn Vancomycin The therapeutic efficacy of Vancomycin can be decreased when used in combination with Cholestyramine. Approved Warfarin Cholestyramine can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Zaltoprofen Cholestyramine can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Zileuton Cholestyramine can cause a decrease in the absorption of Zileuton resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Withdrawn Zomepirac Cholestyramine can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy. Withdrawn - Food Interactions
- Take with food, do not mix with soft drinks.
References
- Synthesis Reference
Moh. S. Amer, Jack C. Gray, "Cholestyramine compositions and method for preparation thereof." U.S. Patent US4895723, issued March, 1967.
US4895723- General References
- Not Available
- External Links
- PubChem Substance
- 46506251
- ChEMBL
- CHEMBL1201625
- PharmGKB
- PA448974
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Cholestyramine
- ATC Codes
- C10AC01 — Colestyramine
- AHFS Codes
- 24:06.04 — Bile Acid Sequestrants
- MSDS
- Download (74.1 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- A-S Medication Solutions LLC
- Bristol-Myers Squibb Co.
- Catalent Pharma Solutions
- Eon Labs
- Major Pharmaceuticals
- Mead Johnson and Co.
- Medisca Inc.
- Novopharm Ltd.
- Par Pharmaceuticals
- Physicians Total Care Inc.
- Upsher Smith Laboratories
- Dosage forms
Form Route Strength Kit; powder Oral 4 g Powder, for suspension Oral 4 g/9g Powder, for suspension Oral 4 g Powder, for suspension Oral 4 g/5g Powder, for suspension Oral 4 g/5.5g Powder, for suspension Oral 4 g/5.7g Powder; suspension Oral 4 g Powder, for suspension Oral 400 g Powder, for solution Oral 400 g Powder Oral 4 g Powder, for solution Oral 4 g Tablet Oral 1 g - Prices
Unit description Cost Unit Questran Light 4 gm/dose Powder 210 gm Can 116.3USD can Questran 4 gm/dose Powder 378 gm Can 115.62USD can Questran Light 4 gm/dose Powder 268 gm Can 102.35USD can Cholestyramine 4 gm/dose Powder 378 gm Can 57.99USD can Cholestyramine Light 4 gm/dose Powder 210 gm Can 57.99USD can Cholestyramine resin powder 16.83USD g Questran 4 gm Packets 4.4USD packet Questran light packet 4.25USD each Questran packet 4.23USD each Cholestyramine 4 gm Packets 3.5USD packet Cholestyramine Light 4 gm Packets 3.49USD packet Cholestyramine light packet 3.35USD each Prevalite packet 2.58USD each Pms-Cholestyramine Light 4 g Powder Packet 1.41USD packet Pms-Cholestyramine Regular 4 g Powder Packet 1.41USD packet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Insoluble Not Available - Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Targets
1. Bile acids
Yes
Binder
References
- Nichifor M, Cristea D, Mocanu G, Carpov A: Aminated polysaccharides as bile acid sorbents: in vitro study. J Biomater Sci Polym Ed. 1998;9(6):519-34. [PubMed:9659597]
- Benson GM, Alston DR, Hickey DM, Jaxa-Chamiec AA, Whittaker CM, Haynes C, Glen A, Blanchard S, Cresswell SR, Suckling KE: SK&F 97426-A: a novel bile acid sequestrant with higher affinities and slower dissociation rates for bile acids in vitro than cholestyramine. J Pharm Sci. 1997 Jan;86(1):76-81. [PubMed:9002463]
Drug created on July 24, 2007 12:41 / Updated on June 18, 2018 22:11